Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Von Willebrand Factor in Menorrhagia

Reducing bleeding in women with von Willebrand disease

Publish date:: February 10, 2016

Von Willebrand factor (VWF) safely and effectively reduces menorrhagia in women with von Willebrand disease (VWD), according to a survey of 20 hemophilia treatment center (HTC) physicians and literature review. Researchers found:

Of 1,321 women with VWD seen by HTC physicians, 61.8% had menorrhagia.

Most common first-line therapies for menorrhagia were a combination of oral contraceptives, tranexamic acid, and desmopressin.

VWF was third-line therapy in 13 patients (1.6%).

Together with data from 88 women from 6 published studies, VWF safely reduced menorrhagia in 101 women at a dose of 33 to 100 IU kg^-1 on day 1 to 6 of the menstrual cycle.

Citation: Ragni MV, Machin N, Malec LM, et al. Von Willebrand factor for menorrhagia: a survey and literature review. [Published online ahead of print February 4, 2016]. Haemophilia. doi: 10.1111/hae.12898.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,